Design Therapeutics (DSGN) AI Stock Analysis

• Market Cap: $677.78M
• Dividend Yield: N/A
• Average Volume (3M): 213.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: N/A
• EPS Growth: -40.26%
• Country: US
• Employees: 56
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 61,672,280
• 10 Day Avg. Volume: 267,018
• 30 Day Avg. Volume: 213,565
• PEG Ratio: -0.20
• Price to Book (P/B): 2.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.86
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.84K
• Enterprise Value/Ebitda: -7.73
• 1Y Price Target: $15.50
• Price Target Upside: 73.38% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -1.35
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $11.50 ▲(28.64% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

Moderate score driven by weak financial fundamentals (no revenue, ongoing losses and rising cash burn) despite a low-debt balance sheet. Technicals are a relative positive with price above major moving averages and improving momentum, while valuation remains pressured due to unprofitability and no dividend support.

Positive Factors

Low Financial Leverage

Very low debt relative to equity gives the company structural financial flexibility and lowers near-term leverage risk. For a development-stage biotech this reduces bankruptcy probability and preserves options to raise non-debt funding or enter partnerships to advance R&D over the next several quarters.

Targeted R&D Platform

A focused discovery platform targeting nucleotide repeat expansions concentrates expertise on a defined class of genetic diseases. That specialization can produce multiple indication opportunities, create competitive differentiation versus broad-based rivals, and remain strategically relevant as genetic therapies gain clinical traction.

Partnership Monetization Pathway

As a pre-commercial biotech, reliance on collaborations is a durable business model to fund development. Structured deals (upfronts, milestones, royalties) can de-risk programs, supply non-dilutive capital and support multi-program advancement over months to years without needing product revenue.

Negative Factors

No Product Revenue

The absence of recurring product revenue is a persistent structural limitation: the company relies entirely on financing and partnerships to fund operations. Without commercialization, cash needs remain high and the firm's ability to self-fund clinical progress is constrained over the medium term.

Rising Cash Burn

Operating cash flow deterioration indicates accelerating cash consumption to support development. Higher burn shortens runway, increases financing frequency, and can force prioritization of programs, slowing development timelines and increasing dilution or dependence on external partners.

Eroding Equity / Funding Pressure

Material declines in shareholders' equity over several years reflect sustained losses and cash drawdown. This trend signals elevated future financing needs and a higher probability of dilution or aggressive partnership terms, limiting strategic optionality for program advancement without external capital.

Design Therapeutics Business Overview & Revenue Model

Company Description

Design Therapeutics (DSGN) is a biotechnology company focused on developing novel therapies for serious degenerative diseases caused by nucleotide repeat expansions. The company operates within the pharmaceutical and biotechnology sectors, leveraging its GeneTAC platform to design small-molecule treatments that target the underlying genetic causes of these diseases. Design Therapeutics aims to address unmet medical needs in conditions such as Friedreich ataxia and other similar genetic disorders.

How the Company Makes Money

Design Therapeutics does not have established, recurring revenue from marketed products; details of ongoing product-sales revenue are not available (null). The company has historically funded operations primarily through financing activities typical of clinical-stage biotechnology firms (e.g., equity offerings and other capital-raising transactions), rather than operating revenue from commercialization. If and when it enters collaborations, it may generate operating revenue from partnership arrangements such as upfront payments, research funding, milestone payments tied to development/regulatory events, and royalties on partnered product sales; however, specific current partnership revenue streams and material commercial agreements are not available here (null).

Design Therapeutics Financial Statement Overview

Summary

Development-stage profile with essentially no revenue and persistent losses; net loss and cash burn worsened in 2025. Offsetting strength is a low-debt balance sheet, though equity has declined meaningfully over time.

Income Statement

Across the annual periods provided (2020–2025), the company reports essentially no revenue, consistent with a pre-commercial biotechnology profile. Losses remain large and persistent, with net income worsening in 2025 versus 2024 (about -$69.8M vs. -$49.6M), indicating rising operating spend. A positive offset is that the loss level has fluctuated year-to-year (not a straight deterioration), but overall profitability is weak and visibility is limited without a revenue base.

Balance Sheet

The balance sheet is a relative strength: debt is very low versus equity (debt-to-equity around 0.3% in 2025 and below ~1.1% across recent years), suggesting limited financial leverage risk. However, equity has declined meaningfully from 2021 to 2025 (roughly $382M to $213M), reflecting ongoing losses and cash usage. Returns on equity are negative in most years, consistent with the company being in an investment phase rather than earning on its capital.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are negative every year shown, and the annual cash burn increased in 2025 versus 2024 (operating cash flow about -$54.4M vs. -$43.1M). Free cash flow broadly tracks net income (free cash flow to net income ~1.0), which suggests losses are largely cash-backed rather than accounting-only. While free cash flow improved versus 2023, overall funding needs remain high given the sustained negative cash flow profile.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-622.00K	-596.00K	-537.00K	-466.00K	0.00
EBITDA	-78.84M	-48.99M	-66.33M	-62.84M	-35.70M
Net Income	-69.79M	-49.59M	-66.86M	-63.31M	-35.53M
Balance Sheet
Total Assets	226.20M	252.09M	289.64M	341.14M	390.56M
Cash, Cash Equivalents and Short-Term Investments	219.84M	245.48M	281.80M	330.39M	384.06M
Total Debt	645.00K	2.33M	3.05M	3.69M	3.63M
Total Liabilities	13.70M	10.00M	11.96M	13.83M	8.43M
Stockholders Equity	212.50M	242.10M	277.69M	327.31M	382.13M
Cash Flow
Free Cash Flow	-54.55M	-43.45M	-58.82M	-52.23M	-30.91M
Operating Cash Flow	-54.36M	-43.10M	-58.56M	-51.32M	-29.38M
Investing Cash Flow	22.91M	43.95M	52.54M	-220.99M	-53.64M
Financing Cash Flow	25.74M	513.00K	724.00K	235.00K	379.21M

Design Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DSGN, the sentiment is Positive. The current price of 8.94 is below the 20-day moving average (MA) of 10.29, below the 50-day MA of 10.04, and above the 200-day MA of 7.04, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 61.53 is Neutral, neither overbought nor oversold. The STOCH value of 50.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DSGN.

Design Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DSGN	57 Neutral	$677.78M	-7.71	-32.72%	―	―	-40.26%
ANNX	56 Neutral	$827.85M	-2.07	-92.28%	―	―	-35.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASMB	49 Neutral	$454.58M	-5.33	-59.01%	―	31.30%	32.79%
KRRO	47 Neutral	$181.72M	-0.64	-63.46%	―	―	21.61%
LXEO	46 Neutral	$479.53M	―	-90.49%	―	―	4.97%
AURA	42 Neutral	$428.01M	-3.90	-69.67%	―	―	-11.41%

Design Therapeutics Corporate Events

Design Therapeutics announces governance-driven board resignation

On January 29, 2026, Design Therapeutics, Inc. announced that board member Deepa Prasad had notified the company of her decision to resign from its Board of Directors, effective February 1, 2026. The departure results from conflict-avoidance policies tied to her newly appointed role at a major bank, indicating a governance-driven board change that may prompt the company to reassess its board composition and expertise mix.

The most recent analyst rating on (DSGN) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Design Therapeutics stock, see the DSGN Stock Forecast page.